Sathgen Therapeutics announces dosing of the first patient cohort with MSP008-22, a novel anti-cancer drug
(Adnkronos) – ~ Promising Efficacy Against Difficult-to-treat Cancers, Including Triple Negative Breast Cancer, and Enhanced Effect of Standard-of-Care Chemotherapy During Preclinical Development ~ MUMBAI, India, July 20, 2023 /PRNewswire/ — Sathgen Therapeutics, a
